An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
about
Chronic myeloid leukemia: reminiscences and dreamsImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationSelecting the best frontline treatment in chronic myeloid leukemiaTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaPredictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyureaHematopoietic stem cell transplantation for leukemiaTrends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisChronic myeloid leukemia: a minimalistic view of post-therapeutic monitoringSuccess story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.Nanotechnology applications in hematological malignancies (Review).Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?First-line treatment of chronic myeloid leukaemia.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Applying the discovery of the Philadelphia chromosome.Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fateEfficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemiaChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Is imatinib still the best choice as first-line oral TKI.Development of an effective therapy for chronic myelogenous leukemiaThe Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia.Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
P2860
Q26748769-EDD019B7-191C-4949-AAB4-397BF639015DQ28068378-18C4F390-DAEC-463F-80D9-7F9DE16FA934Q33764253-2D9E6FEC-785A-4BA3-8FE3-EEC6277EE808Q33806617-865AB9FA-20E8-455B-8CC1-616DD56E6DC0Q33857947-DA1EC79C-CC4C-49E5-8DFD-F27BFF25DACBQ33890580-8488AC68-33B4-41D8-A251-1232CD2DF68AQ33903030-BE4D9AC5-ED9B-4F60-B10D-16AF66EED84BQ33965782-0FA4719A-465F-4F4F-B06E-B91B8F4611AAQ34034180-217A8203-F4C7-4BF1-B4E9-9DEBCDB5200AQ34445704-E9FA436B-D22A-483A-AF28-C781F0006E58Q34516009-4E5E4A36-E8AA-41ED-835C-B03CDBAEA765Q35112049-FD2F2134-F3B4-4336-8C96-4D58A656A1ECQ35876347-06CEFA1A-BAF7-4154-99B8-2E0BE77BF398Q35934466-A445F521-28F7-4444-98BD-896C5DA8539AQ36089086-EE2EE124-29CC-4E74-B358-6B86F7B52A85Q36263943-34794A47-516A-4475-82AE-91706B58CB11Q36545339-B0DBCA9D-57D7-40D2-A653-AF01B7665003Q36612527-5D7729AD-C48F-4736-8753-CCFCC2FF57FAQ36822880-F8726C00-B54A-4CDB-BA45-0479B5A24C0BQ36900109-E5B50645-C60C-479D-B7DC-6929F9CB1D13Q37115618-B6A86F88-2EAE-4D69-A9B2-0D6CF6D4394EQ37150014-7378D3D2-6FE6-468F-BA23-7B1408D1E3C6Q37163550-0EF1BFC1-F106-4C8C-9400-9368866EB8AEQ37654034-82A9B8D3-19C4-4157-B415-670734E7488BQ37966917-D1E7501D-D728-49D2-987E-1740F2A5FB35Q38290361-1C969335-28F4-48D3-9D57-A301F8B91AC3Q40178701-080536CB-B0CE-4192-9727-E6C9F12384A3Q42316987-F7EF123E-39FC-452D-95A6-7485CD40E1F1Q54123354-F4AD8C9E-30F6-41A6-9225-93CFA3B7B00DQ57069646-F737F8EA-A010-4816-8A69-F30776F8E327
P2860
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
An evidence-based analysis of ...... merican Society of Hematology.
@ast
An evidence-based analysis of ...... merican Society of Hematology.
@en
type
label
An evidence-based analysis of ...... merican Society of Hematology.
@ast
An evidence-based analysis of ...... merican Society of Hematology.
@en
prefLabel
An evidence-based analysis of ...... merican Society of Hematology.
@ast
An evidence-based analysis of ...... merican Society of Hematology.
@en
P2093
P1433
P1476
An evidence-based analysis of ...... merican Society of Hematology.
@en
P2093
Anderson J
Goldman JM
Hehlmann R
Kantarjian HM
Lichtin AE
P304
P407
P577
1999-09-01T00:00:00Z